Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MGC018 + Retifanlimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGC018 | CD276 Antibody 8 | MGC018 is a humanized monoclonal anti-B7-H3 (CD276) antibody in conjugation with a cytotoxic agent (vc-seco-DUBA), which may specifically target B7-H3-expressing tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 820, PMID: 32967924). | ||
Retifanlimab | MGA 012|INCMGA00012|MGA012 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03729596 | Phase Ib/II | MGC018 MGC018 + Retifanlimab | MGC018 With or Without MGA012 in Advanced Solid Tumors | Active, not recruiting | USA | ESP | 2 |